Skip to main content

BGB-290 and Temozolomide in Treating Adolescents and Young Adults with IDH1 / 2-Mutant Newly Diagnosed or Recurrent Grade I-IV Gliomas

Trial Status: Active

This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1 / 2-mutant grade I-IV glioma that is newly diagnosed or has come back (recurrent). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as BGB-290, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Drugs used in chemotherapy, such as temozolomide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating adolescents and young adults with IDH1 / 2-mutant grade I-IV glioma.

Inclusion Criteria

  • Arm A Only: Subjects must have histologically confirmed World Health Organization (WHO) grade III-IV newly diagnosed IDH1/2-mutant glioma.
  • Arm B Only: WHO grades I-IV recurrent IDH1/2 mutant glioma. Subjects in Arm B must have magnetic resonance imaging (MRI) confirming progressive disease; re-biopsy is encouraged, but not required at the time of recurrence for confirmation.
  • Patients with a primary spinal tumor, secondary glioma, or multifocal disease in the brain, but without evidence of diffuse leptomeningeal spread, are eligible. In cases where there are questions about multifocality versus diffuse leptomeningeal spread, the study chair or co-chair must be contacted to make a final decision on eligibility.
  • Subjects must have IDH1 or IDH2 mutation associated with neomorphic activity of the encoded proteins.
  • Subjects must be willing to provide archival formalin-fixed embedded (FFPE) and frozen tissue specimens for biomarker studies if available.
  • Subjects in Arm A must have been treated with maximal safe resection of primary tumor followed by adjuvant radiation therapy (RT). Treatment with TMZ during radiation is allowed but not required.
  • Subjects in Arm B must have been treated with maximal safe resection of tumor. * Lower grade glioma (LGG) subjects who progressed after initial surgery alone are eligible. Any number of prior therapies are allowed. * High grade glioma (HGG) subjects enrolled on Arm B must have been treated with a minimum of maximal safe resection of primary tumor followed by adjuvant RT prior to recurrence. Any number of prior therapies are allowed.
  • Subjects must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
  • Myelosuppressive chemotherapy: subjects must have received their last dose of known myelosuppressive anticancer chemotherapy at least three weeks prior to study registration or at least six weeks if nitrosourea.
  • Biologic agent: subjects must have recovered from any toxicity related to biologic agents and received their last dose >= 7 days prior to study registration. * For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval should be discussed with the study chair. * For biologic agents that have a prolonged half-life, the appropriate interval since last treatment should be discussed with the study chair prior to registration.
  • Monoclonal antibody treatment: at least three half-lives must have elapsed prior to registration, and subjects on bevacizumab must have received their last dose >= 32 days prior to study registration.
  • Subjects in Arm A should begin therapy with TMZ and BGB-290 4-6 weeks after completion of radiation therapy and when all other eligibility criteria are met.
  • For subjects in Arm B, patients must not have received radiation therapy within 4 weeks prior to the initiation of study treatment. Post-RT, the diagnosis of true progression versus “pseudo-progression” can be challenging when imaging modalities are exclusively used, and thus an additional resection is encouraged if clinically indicated.
  • Peripheral absolute neutrophil count (ANC) >= 1000/mm^3.
  • Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).
  • Hemoglobin >= 9 g/dL.
  • Serum creatinine =< 1.5 x upper limit of normal (ULN) or estimated creatinine clearance >= 50 mL/min (calculated using the institutional standard method).
  • Total serum bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN).
  • Aspartate and alanine aminotransferase (AST and ALT) =< 3 x ULN.
  • Serum albumin >= 2 g/dL.
  • Subjects with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled.
  • Subjects who have neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration.
  • Corticosteroids: Subjects who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration.
  • The effects of BGB-290 on the developing human fetus are unknown. For this reason and because alkylating agents (such as TMZ) are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 4 months after completion of BGB-290 or TMZ administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • Subjects must be able to swallow capsules.
  • Subjects must have the ability to undergo serial MRI scans (computerized tomography [CT] cannot substitute for MRI).
  • A legal parent/guardian or patient must be able to understand, and willing to sign, a written informed consent and assent document, as appropriate.
  • Karnofsky >= 50 for subjects > 16 years of age and Lansky >= 50 for subjects =< 16 years of age. Subjects who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

Exclusion Criteria

  • Subjects who are receiving any other investigational agents and/or subjects previously treated with small molecule inhibitors of mutant IDH1 or IDH2 proteins at any time may not be enrolled.
  • Subjects who have received a PARP inhibitor previously.
  • Subjects with active infection requiring antibiotics at time of therapy start.
  • Subjects with other diagnosis of malignancy.
  • Subjects with clinically significant active bleeding disorder, hemoptysis, or melena =< 6 months prior to day 1.
  • Subjects on therapeutic anti-coagulation with heparin, warfarin, or other anticoagulants: * Use of low-dose aspirin and/or non-steroidal anti-inflammatory agents are allowed. * Use of thrombolytics to establish patency of indwelling venous catheters is allowed. * Prophylactic anticoagulation for venous access devices is allowed as long as institutional normalized ratio (INR) is =< 1.5 and partial thromboplastin time (aPTT) =< 1.5 x institutional ULN. * Use of low-molecular weight heparin is allowed.
  • Subjects with known disseminated leptomeningeal disease.
  • Subjects with DIPG (diffuse intrinsic pontine glioma) are not eligible for this study.
  • Unresolved acute effects of any prior therapy of grade >= 2, except for adverse events (AEs) not constituting a safety risk by investigator judgement.
  • Use =< 10 days (or =< 5 half-lives, whichever is shorter) prior to day 1 or anticipated need for food or drugs known to be strong or moderate CYP3A inhibitors or strong CYP3A inducers.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to TMZ or BGB-290.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Female subjects of childbearing potential must not be pregnant or breast-feeding. Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 7 days of first dose.
  • Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with BGB-290 and TMZ. In addition, these subjects are at increased risk of lethal infections when treated with marrow-suppressive therapy.
  • Subjects with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.


Los Angeles
Children's Hospital Los Angeles
Contact: Ashley Sloane Margol
Phone: 323-361-8147
Mattel Children's Hospital UCLA
Contact: Tom Belle Davidson
Phone: 310-825-6708
UCSF Benioff Children's Hospital Oakland
Contact: Tabitha Michelle Cooney
Phone: 510-428-3885ext3398
San Diego
Rady Children's Hospital - San Diego
Contact: John Ross Crawford
Phone: 858-966-4939
San Francisco
UCSF Medical Center-Mount Zion
Status: ACTIVE
Contact: Sabine Mueller
Phone: 415-476-3831
University of California San Francisco
Status: ACTIVE
Contact: Sabine Mueller
Phone: 415-476-3831


New Haven
Yale University
Contact: Asher Michael Marks
Phone: 203-785-4640

District of Columbia

Children's National Medical Center
Contact: Lindsay Baker Kilburn
Phone: 202-476-5973


University of Florida Health Science Center - Gainesville
Contact: Sridharan Gururangan
Phone: 352-294-8347


Lurie Children's Hospital-Chicago
Contact: Stewart Goldman
Phone: 312-227-4873


Johns Hopkins University / Sidney Kimmel Cancer Center
Status: ACTIVE
Contact: Kenneth J. Cohen
Phone: 410-614-5055


Dana-Farber Cancer Institute
Status: ACTIVE
Contact: Susan N. Chi
Phone: 617-632-2291
Massachusetts General Hospital
Contact: David H. Ebb
Phone: 617-726-2737


University of Minnesota / Masonic Children's Hospital
Contact: Christopher Loren Moertel
Phone: 612-626-2778


Saint Louis
Washington University School of Medicine
Status: ACTIVE
Contact: Karen M. Gauvain
Phone: 314-286-2790


Nationwide Children's Hospital
Contact: Mohamed Shebl Abdelbaki
Phone: 614-722-4087


Oregon Health and Science University
Status: ACTIVE
Contact: Kellie Jean Nazemi
Phone: 614-722-4087


Children's Hospital of Philadelphia
Contact: Jane E. Minturn
Phone: 267-426-5026


Saint Jude Children's Research Hospital
Contact: Amar Gajjar
Phone: 901-595-2615


Texas Children's Hospital
Contact: Patricia Ann Baxter


Salt Lake City
Huntsman Cancer Institute / University of Utah
Contact: Nicholas Shawn Whipple
Phone: 801-662-4700


Seattle Children's Hospital
Contact: Sarah E. S. Leary
Phone: 206-667-7995


Hospital for Sick Children
Contact: Eric Bouffet
Phone: 416-813-7360


I. Determine the safety and tolerability of the combination of pamiparib (BGB-290) and temozolomide (TMZ) in adolescent and young adult (AYA) subjects with IDH1/2-mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in both, newly diagnosed and recurrent treatment arms.


I. Evaluate the preliminary efficacy of BGB-290 and temozolomide in terms of progression free survival (PFS) and overall survival (OS) in Arm A and B stratified by tumor diagnosis, calculated using the Kaplan-Meier method with a goal of improving the historical high grade glioma progression free survival of 10% and overall survival of 20% at 2 years.

II. Assess the mutational landscape studies via whole-exome sequencing (WES).

III. Assessment of gene expression patterns using ribonucleic acid (RNA) sequencing (RNAseq).

IV. Assess the methylation profiling with Infinium methylation assays.

V. Assess the oncometabolite profiling via liquid chromatography (LC)/mass spectrometry (MS)-MS.

VI. Assess the intratumoral drug level assessments via LC/MS-MS.

VII. To assess quality of life (QOL) and cognitive measures in adolescent and young adult patients with newly diagnosed and recurrent mutant gliomas.

OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 2 cohorts. After the MTD is established, additional patients will be enrolled into the efficacy component of the trial.

COHORT A: Patients receive pamiparib orally (PO) twice daily (BID) on days 1-28 and temozolomide PO daily on days 1-21. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.

COHORT B: Patients receive pamiparib PO BID for 7 days. Patients then receive pamiparib and temozolomide as in Cohort A.

COHORT B0: Patients receive pamiparib PO for 7 days pre-surgery at the MTD determined in the Phase I portion. After recovery from surgery (14-28 days), the patient will proceed to the efficacy component of the trial.

After completion of study treatment, patients are followed up for 5 years.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
University of California San Francisco

Principal Investigator
Sabine Mueller

  • Primary ID 18083
  • Secondary IDs NCI-2018-02345, PNOC017, 18-25253
  • ID NCT03749187